Another piece of bad news has come out for St. Jude Medical (NYSE: STJ) regarding an FDA report on defibrillator lead Durata, bringing shares down 12%. In this video, Motley Fool health-care analyst David Williamson talks about how these findings add to a recent string of product difficulties for St. Jude, and how, as an investor, if you see this as the company turning a corner, then it could be a cheap entry point.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
More Bad News for St. Jude
By Dave Williamson and Brenton Flynn
–
Nov 22, 2012 at 7:00AM
NYSE: STJ
St. Jude Medical Inc.
More bad news for a company already plagued by product problems.
Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Medtronic and St. Jude Medical. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
St. Jude Medical Inc.
STJ
Boston Scientific
BSX
$104.36
(1.12%)
$1.16
Medtronic
MDT
$89.72
(-0.22%)
$0.20
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why St. Jude Medical, Inc. Acquired a Higher Price Today
How Big Is the St. Jude Medical Threat to Abiomed, Inc. Stock?
3 Charts Show Why Abiomed Could Get Bought
Why Abiomed Shares Jumped 13% in March
Why Abiomed, Inc. Shares Were Sent Soaring 137% in 2015
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.